Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Baron, Frédéric  [Clear All Filters]
2022
Ruggeri A, Galimard J-E, Labopin M, Rafii H, Blaise D, Ciceri F, Diez-Martin J-L, Cornelissen J, Chevallier P, Sanchez-Guijo F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. Transplant Cell Ther. 2022.
2021
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
Pirotte M, Fillet M, Seidel L, Jaspers A, Baron F, Beguin Y. ERYTHROFERRONE AND HEPCIDIN AS MEDIATORS BETWEEN ERYTHROPOIESIS AND IRON METABOLISM DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT. Am J Hematol. 2021.
2020
Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, Fazi P, Vignetti M, Marie J-P, Chiusolo P, et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: long-term follow up of a phase III study. Am J Hematol. 2020.
2018
Delens L, Ehx G, Somja J, Vrancken L, Belle L, Seidel L, Grégoire C, Fransolet G, Ritacco C, Hannon M, et al. In vitro Th17-polarized human CD4 T cells exacerbate xenogeneic graft-versus-host disease. Biol Blood Marrow Transplant. 2018.
Pirotte M, Forte F, Lutteri L, Willems E, Duran U, Belle L, Baron F, Beguin Y, Maquet P, Bodart O, et al. Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Neuroimmunol. 2018;323:115-118.
2016
Servais S, Beguin Y, Delens L, Ehx G, Fransolet G, Hannon M, Willems E, Humblet-Baron S, Belle L, Baron F. Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Expert Opin Investig Drugs. 2016.
Giebel S, Czyż A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin N-C, Savani B, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of the . Cancer. 2016.
2015
de Witte T, Suciu S, Meert, iv L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). Ann Hematol. 2015.
Servais S, Menten-Dedoyart C, Beguin Y, Seidel L, Gothot A, Daulne C, Willems E, Delens L, Humblet-Baron S, Hannon M, et al. Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS One. 2015;10(6):e0130026.
Holter-Chakrabarty JL, Pierson N, Zhang M-J, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, et al. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplant for Patients with Acute Leukemia. Biol Blood Marrow Transplant. 2015.
2014
Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, et al. Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. PLoS One. 2014;9(11):e113764.